Background: The approval of Osimertinib in Brazil in 2016 for post EGFR-TKI progression T790M+ NSCLC treatment allowed offering to the patient the best available therapy, when, it is mandatory to identify the occurrence of T790M mutation before initiating the treatment. However, there is lack of data in Brazil from ct-DNA T790M detection in this patient set. Method: We performed a retrospective analysis of a database of ctDNA samples collected between June 2016 and August 2017, from all Brazilian regions, positive for T790M and also primary EGFR mutation. Blood samples of patients with post EGFR-TKI progression were submitted, at the discretion of the attending physicians, for EGFR mutation testing. EGFR exons 18 to 21 were analyzed by cobas ® . Prevalence of T790M mutation was not the objective of this analysis, since it considered only the positive T790M and primary mutation in ctDNA. Results: 115 results were included in this analysis. 62.6% of the population was female; 94.8% of positive primary and T790M mutations were related do exon 19 deletion or L858R. There were no differences in frequency distribution between female and male population (Table 1) . These frequencies were compatible with demographic data of AURA3 study. Still, more detailed testing using tissue and/or more sensitive methods are needed before a definitive conclusion. Table1 e Concomitant primary EGFR and T790M mutations in post EGFR-TKI progression in Brazil detected by cobas® test. Conclusion: Our findings in Brazilian population demonstrated that there were no differences in frequency of T790M according to primary mutation between post EGFR-TKI progressive NSCLC female and male population detected by ctDNA cobas® test. Background: Lung cancer is the most common cancer diagnosis and the leading cause of cancer-related death worldwide. CNS metastasis is usual in non-small-cell lung cancer (NSCLC), with an increased risk in EGFR-mutated tumors at the time of diagnosis as well as during disease course. Osimertinib is the standard of care for patients with metastatic EGFR T790M mutationepositive NSCLC following prior treatment with an EGFR-TKI, with demonstrated efficacy against CNS metastasis. Method: ASTRIS is a phase IV, multinational, open-label trial of osimertinib for advanced T790M mutation NSCLC who received prior EGFR-TKI. Patients with CNS symptomatic disease were excluded. CNS metastasis screening were not mandatory in asymptomatic patients. Data presented here refer to the subset of Brazilian patients with CNS metastasis from the 14 participant sites. Results: From August 2015 until March 2017, a total of 88 patients were included with a median age of 64 years (34-89), 66% female, and only 12.5% with PS2. Fiftyfour patients (61%) had received prior therapy with erlotinib, fortytwo (48%) with gefitinib, and 3 (3%) with afatinib. Only 46 patients (52%) had baseline brain scans. Magnetic resonance imaging (MRI) was performed in 81% and computed tomography (CT) in 19% of them. From this subgroup, a total of 25 patients (54%) had CNS metastasis; twenty-two (88%) with brain metastasis only, one (4%) with leptomeningeal disease only, and 2 (8%) with both presentation. Molecular testing was performed less often in tissue (40%), coming from metastatic site in 70% of cases. None of these biopsies came from CNS metastasis. Exon 19 deletions were the most common primary mutation in EGFR, present in 18 cases (72%), followed by L858R in 4 cases (16%), similar to non-CNS metastasis cohort. Of note, 2 cases (8%) harbored an exon 20 insertion. After a median follow-up of 9.3 months, 9 progression events (36% of patients) and 4 deaths (16%) were documented. Response evaluation was performed in 22 patients. The response rate was 59% (95%CI 36.4-79.3), compared to 58.2% (95%CI 46.6-69.2) in the total cohort of patients. At time of progression 33% had stable and 67% progressive CNS disease. Conclusion: Realworld data may differ from controlled clinical trial, especially concerning patient selection. In this trial, results are consistent with previous reports of CNS response to osimertinib in patients with T790M-positive advanced NSCLC. However, very few patients were routinely screened for CNS metastasis, raising the question about the importance of a formal screening recommendation in this high-risk population. Journal of Thoracic Oncology Vol. 13 No. 9S: S158-S160
